Aliso Viejo-based Valeant Pharmaceuticals International said Friday that GlaxoSmithKline PLC is going to market Valeant’s Diastat AcuDial seizure drug in the U.S.
Financial terms weren’t disclosed.
GlaxoSmithKline, a British drug maker, will market Diastat AcuDial to U.S. doctors in 2009.
The deal could be extended if Valeant and GlaxoSmithKline agree to do so. Valeant said it would record the drug’s revenue and be responsible for product development and brand strategy.
Diastat AcuDial is used for what’s called breakthrough seizures, or a group of seizures experienced by patients who are already on epilepsy medication. Diastat AcuDial accounted for $12.1 million in revenue in 2007, unchanged from the previous year.
Valeant also has a development deal with GlaxoSmithKline for retigabine, an epilepsy drug candidate that’s in late-stage clinical trials. Valeant received a $125 million payment earlier this month from GlaxoSmithKline for retigabine.
Valeant could receive up to $825 million in the earlier deal, which also includes VRX698, another drug candidate.
